ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company

Author's Avatar
Jul 16, 2019
Article's Main Image

-Assets Include Preclinical and Clinical Programs, Technology, Intellectual Property and Know-how-

-Completion of Sale Pending Certain Conditions-

-Company Continuing to Seek Strategic Alternatives, Including a Reverse Merger-

PR Newswire